Amgen Surges to 153rd in Trading Activity with $0.75 Billion Volume Spike

On September 18, 2025, , . The stock ranked 153rd in trading activity among listed equities, .

Recent developments highlight regulatory scrutiny intensifying around Amgen’s biosimilar pipeline. The FDA has requested additional data on three key biosimilar candidates, including AMG 714, which targets the rheumatoid arthritis market. , potentially ceding market share to competitors in high-margin therapeutic segments.

Meanwhile, investor sentiment remains mixed regarding the company’s Q3 earnings outlook. While management reaffirmed full-year revenue guidance during a recent investor call, . Medicare Part D program. , suggesting reduced bearish positioning ahead of earnings.

Backtesting analysis of a volume-based portfolio strategy reveals limitations in multi-asset testing capabilities. The current system supports single-security evaluations only, requiring either a narrowed scope to a single ETF like SPY or separate tests on a fixed set of high-liquidity tickers. Alternative workflows for multi-asset portfolios are under investigation but remain constrained by data processing boundaries.